CytomX Therapeutics Inc
NASDAQ:CTMX

Watchlist Manager
CytomX Therapeutics Inc Logo
CytomX Therapeutics Inc
NASDAQ:CTMX
Watchlist
Price: 1.01 USD -2.88% Market Closed
Market Cap: 78.9m USD
Have any thoughts about
CytomX Therapeutics Inc?
Write Note

Wall Street
Price Targets

CTMX Price Targets Summary
CytomX Therapeutics Inc

Wall Street analysts forecast CTMX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CTMX is 5.42 USD with a low forecast of 3.54 USD and a high forecast of 8.4 USD.

Lowest
Price Target
3.54 USD
250% Upside
Average
Price Target
5.42 USD
436% Upside
Highest
Price Target
8.4 USD
732% Upside

CTMX Last Price Targets
CytomX Therapeutics Inc

The latest public price target was made on Nov 8, 2024 by Joseph Catanzaro from Piper Sandler , who expects CTMX stock to rise by 222% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Joseph Catanzaro
Piper Sandler
3.25 USD
Upside 222%
6 days ago
Nov 8, 2024
CytomX Therapeutics (CTMX) PT Lowered to $3.25 at Piper Sandler
StreetInsider
Etzer Darout
BMO Capital
3.68 USD
Upside 264%
6 days ago
Nov 8, 2024
CytomX Therapeutics (CTMX) PT Raised to $3.68 at BMO Capital
StreetInsider
Etzer Darout
BMO Capital
3.56 USD
Upside 252%
3 months ago
Aug 9, 2024
CytomX Therapeutics (CTMX) PT Lowered to $3.56 at BMO Capital
StreetInsider
Joseph Catanzaro
Piper Sandler
3.5 USD
Upside 247%
5 months ago
May 27, 2024
CytomX Therapeutics upgraded to Overweight from Neutral at Piper Sandler
TheFly
Robert Driscoll
Wedbush
8 USD
Upside 692%
6 months ago
May 9, 2024
Wedbush Upgrades CytomX Therapeutics (CTMX) to Outperform
StreetInsider
Etzer Darout
BMO Capital
3.59 USD
Upside 255%
6 months ago
May 9, 2024
CytomX Therapeutics (CTMX) PT Raised to $3.59 at BMO Capital
StreetInsider
Roger Song
Jefferies
8 USD
Upside 692%
6 months ago
May 5, 2024
CytomX Therapeutics upgraded to Buy from Hold at Jefferies
TheFly
Roger Song
Jefferies
2.5 USD
Upside 148%
8 months ago
Mar 12, 2024
CytomX Therapeutics (CTMX) PT Raised to $2.50 at Jefferies, 'EGFRxCD3 on Track for Ph1a Data in 2H24'
StreetInsider
Etzer Darout
BMO Capital
3.25 USD
Upside 222%
8 months ago
Mar 12, 2024
CytomX Therapeutics (CTMX) PT Lowered to $3.25 at BMO Capital, 'Pipeline Updates Broadly in Line'
StreetInsider
Show More Price Targets
Show Less Price Targets
Joseph Catanzaro
Piper Sandler
Price Target 3.25 USD
Upside/Downside 222%
View Source
Etzer Darout
BMO Capital
Price Target 3.68 USD
Upside/Downside 264%
View Source
Etzer Darout
BMO Capital
Price Target 3.56 USD
Upside/Downside 252%
View Source
Joseph Catanzaro
Piper Sandler
Price Target 3.5 USD
Upside/Downside 247%
View Source
Robert Driscoll
Wedbush
Price Target 8 USD
Upside/Downside 692%
View Source
Etzer Darout
BMO Capital
Price Target 3.59 USD
Upside/Downside 255%
View Source
Roger Song
Jefferies
Price Target 8 USD
Upside/Downside 692%
View Source
Roger Song
Jefferies
Price Target 2.5 USD
Upside/Downside 148%
View Source
Etzer Darout
BMO Capital
Price Target 3.25 USD
Upside/Downside 222%
View Source
Show More Price Targets
Show Less Price Targets
CytomX Therapeutics Inc Competitors:
Price Targets
APLT
Applied Therapeutics Inc
46% Upside
ASND
Ascendis Pharma A/S
61% Upside
MDGL
Madrigal Pharmaceuticals Inc
17% Upside
ARWR
Arrowhead Pharmaceuticals Inc
123% Upside
IGMS
IGM Biosciences Inc
77% Upside
BIOCON
Biocon Ltd
2% Upside
ORGO
Organogenesis Holdings Inc
1% Upside
086890
Isu Abxis Co Ltd
93% Upside

Revenue
Forecast

Revenue Estimate
CytomX Therapeutics Inc

For the last 8 years the compound annual growth rate for CytomX Therapeutics Inc's revenue is 38%. The projected CAGR for the next 3 years is -30%.

38%
Past Growth
-30%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
CytomX Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
CytomX Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CTMX's stock price target?
Price Target
5.42 USD

According to Wall Street analysts, the average 1-year price target for CTMX is 5.42 USD with a low forecast of 3.54 USD and a high forecast of 8.4 USD.

What is CytomX Therapeutics Inc's Revenue forecast?
Projected CAGR
-30%

For the last 8 years the compound annual growth rate for CytomX Therapeutics Inc's revenue is 38%. The projected CAGR for the next 3 years is -30%.

Back to Top